mesalamine

(redirected from Mesalazine)
Also found in: Medical, Wikipedia.
Related to Mesalazine: mesalamine

me·sal·a·mine

 (mə-săl′ə-mēn′)
n.
A salicylate drug derived from sulfasalazine, C7H7NO3, used primarily to treat inflammatory bowel disease.

Translations

mesalamine

(USAN), mesalazine (INN) n mesalamina, mesalazina (INN)
References in periodicals archive ?
Mesalazine (Asacol) and rifaximin (Xifaxan) are commonly recommended antibiotics for diverticular disease.
drug mesalazine enteric-coated tablets, 500 mg 5,900 units, 8 661.
The vast majority of patients in both groups were treated with mesalazine alone (control group 61.1% and synbiotic group 88.9%).
5-Aminosalicylic acid (mesalazine) was administered, with symptoms remitted after 3 months.
The patient with fundal varices had infantile onset CD as it was diagnosed before the age of six years (at six months specifically), which was managed with mesalazine. At the age of 16, he had an episode of acute abdomen, and CT angiography revealed thrombosis of both superior mesenteric artery and vein.
Patient n = 192 Gender n (%) Female 104 (54.1) Male 88 (45.9) Age, years Median (range) 36 (16-69) Disease duration, years Median (range) 3.3 (0-31) Disease extension n (%) Extensive colitis 117 (60) Left-sided colitis 75 (40) Mayo endoscopic subscore *n (%) Mayo 1 16(9) Mayo 2 91 (52) Mayo 3 68 (39) Smoking habit n (%) Yes 23 (12) No/former smoker 169 (88) Indication for starting thiopurines n (%) Steroid dependency 111 (58) Maintenance after a severe attack 36 (19) Frequent relapses 45 (23) Cotreatment with mesalazine n (%) 175 (91.1) Duration of thiopurine therapy, months Median (range) 36 (1-210) Table 2: Logistic regression analysis of predictors of steroid-free clinical remission.
Turnberg, "Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse," Gut, vol.
All these changes were corrected after treatment of either Portulaca extract or mesalazine. Moreover, mRNA levels of Bcl-2 and Bax showed the same changes as their proteins in the four different groups of mice.
Given the existing uncertainties, mesalazine, an antiinflammatory drug, has been purported as a promising intervention in diverticular disease.
Underpinning the financial results in the period under review is a continued focus on the key growth drivers, encompassing first-to-opportunity generics, such as losartan and mesalazine and proprietary brands, including Po Chai Pills, Ho Chai Kung and Shiling Oil.